Free Newsletter
J&J to cut 900 jobs, mostly in sales
The bell tolls for more pharma sales reps. Johnson & Johnson is cutting 900 jobs at Ortho-McNeil-Janssen pharma unit, Reuters reports, or about 6 percent of its U.S. pharma workforce. Most of the positions going into that good night are sales-rep jobs.
The good news? They're not all layoffs; some of the cuts are happening via attrition. The company refused, however, to say just how many jobs were eliminated that way. Some of the laid-off workers were told last week; the rest, we assume, await their fates.
J&J is just the latest of many drugmakers to slice their workforces. The ranks of sales reps have been hit particularly hard as the industry dials back a huge expansion of its sales operations from the mid-90s to mid-00s. And like other drugmakers, J&J is suffering from an onslaught of generic competition as some of its biggest drugs go off patent.
- read the Reuters news
Related Articles:
Analyst: Contract sales reps rule
Pharma reps between rock and hard place
Even productive reps will be obsolete, PwC says
Whose sales reps are No. 1?
More docs tell pharma reps to keep out
More stories about Johnson & Johnson Pharma sales reps Janssen Pharmaceuticals pharmaceutical layoffs
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: